Glucagon-like Peptide-1 Receptor Agonists in Heart Failure: Mechanisms, Evidence and Identifying Optimal Candidates.

Card Fail Rev · 2025 · PMC12606456 · PMID 41234532

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, the reduction in HF hospitalisations with semaglutide did not reach statistical significance. 9 The STEP-HFpEF DM randomised controlled trial enrolled 616 patients with obesity (BMI ≥30 kg/m 2 ) and both HFpEF (LVEF ≥40%) and T2D. 37 STEP-HFpEF DM specifically investigated the effect of once-weekly subcutaneous semaglutide versus placebo on the primary endpoint of change in KCCQ-CSS at 52 weeks.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.